Abstract:Purpose: Eukaryotic initiation factor 4A-3 (EIF4A3) is an RNA-binding protein (RBP) that is a core component of the exon junction complex (EJC). It has been identified as an important player in post-transcriptional regulation processes. Recently, investigations have focused on EIF4A3 dysfunction in carcinogenesis. The present study aims to determine whether EIF4A3 can serve as a prognostic marker and potential regulatory mechanism in human cancers. Materials and methods: EIF4A3 expression in various cancers was assessed using Oncomine. The Correlation between EIF4A3 expression and patient survival was evaluated using PrognoScan. EIF4A3 mutations in various cancers were investigated using cBioPortal. EIF4A3 co-expression networks in various cancers were established using Coexpedia. Finally, we analyzed potential functional roles of EIF4A3 using Gene Ontology and pathway enrichment analyses by FunRich V3. Results: EIF4A3 was overexpressed in common malignancies at the transcription levels. High incidences of the breast, lung, and urinary cancers were closely related to the prognostic index for survival. The most prevalent mutation in EIF4A3 was E59K/Q. The tumor necrosis factor-α (TNF-α)/nuclear factor-κB (NF-κB) signaling pathway was affected by these mutations. Co-expression networks showed that EIF4A3 regulates apoptosis and cell cycle via several cancer-related signal pathways, and promotes tumor cell migration, invasion and drug resistance. Conclusion: Our results suggest the potential role for EIF4A3 to serve as a diagnostic marker or therapeutic target for certain types of cancers.

Nuclear distribution of eIF3g and its interacting nuclear proteins in breast cancer cells

Eukaryotic Translation Initiation Factor 3 and Tumor

Elevated Nuclear Phospho-Eif4e Body Levels Are Associated with Tumor Progression and Poor Prognosis for Acute Myeloid Leukemia

eIF3i regulation of protein synthesis, cell proliferation, cell cycle progression, and tumorigenesis

eIF3 mRNA selectivity profiling reveals eIF3k as a cancer-relevant regulator of ribosome content

eIF3a: A new anticancer drug target in the eIF family.

Identification of the p28 subunit of eukaryotic initiation factor 3(eIF3k) as a new interaction partner of cyclin D3.

eIF3a Regulation of NHEJ Repair Protein Synthesis and Cellular Response to Ionizing Radiation

Research progress on eIF3 a and cancer

Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers

Eukaryotic Translation Initiation Factor 3 Subunit B Could Serve As a Potential Prognostic Predictor for Breast Cancer

[Expression of (His)(6)-Eif3s4 Fusion Protein in Human Breast Cancer Cell Bcap37].

Recent research progress of eIF3 in biological function

Eif3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response.

Eukaryotic Translation Initiation Factors and Tumor

Eukaryotic Translation Initiation Factor 3b is Both a Promising Prognostic Biomarker and a Potential Therapeutic Target for Patients with Clear Cell Renal Cell Carcinoma.

The Tumor Suppressive Role of eIF3f and Its Function in Translation Inhibition and rRNA Degradation

[Role of Eukaryotic Translation Initiation Factor 4G in Tumor].

Overexpression of Eif3e is Correlated with Colon Tumor Development and Poor Prognosis.

The Biological Roles Of Translation Initiation Factor 3b

Systematic Analysis of Gene Expression Alteration and Co-Expression Network of Eukaryotic Initiation Factor 4A-3 in Cancer